Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 30.0% in January

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 443,900 shares, a growth of 30.0% from the January 15th total of 341,500 shares. Approximately 19.1% of the shares of the company are short sold. Based on an average daily volume of 188,600 shares, the days-to-cover ratio is presently 2.4 days.

Bionano Genomics Stock Performance

NASDAQ:BNGO traded up $0.23 during trading hours on Friday, reaching $5.76. The company had a trading volume of 364,504 shares, compared to its average volume of 286,334. Bionano Genomics has a 1-year low of $4.75 and a 1-year high of $81.00. The firm has a market cap of $11.23 million, a PE ratio of -0.04 and a beta of 2.13. The business’s 50 day moving average price is $10.99 and its 200-day moving average price is $18.86. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Carret Asset Management LLC lifted its holdings in Bionano Genomics by 39.9% in the fourth quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock valued at $34,000 after acquiring an additional 33,945 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Bionano Genomics during the 3rd quarter worth approximately $46,000. Geode Capital Management LLC raised its stake in shares of Bionano Genomics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 997,676 shares of the company’s stock worth $288,000 after buying an additional 114,822 shares during the period. XTX Topco Ltd acquired a new position in shares of Bionano Genomics during the 4th quarter worth approximately $45,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Bionano Genomics during the 4th quarter worth approximately $46,000. 11.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.